← FDA DRUG APPROVALS

FDA ANDA · ANDA089635

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

Sponsor: HOSPIRA

APPLICATION
ANDA089635
TYPE
ANDA
ORIGINAL APPROVAL
1988-06-21
LATEST ACTION
2026-04-01
ROUTE
INFILTRATION, PERINEURAL, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINEPrescription
EPINEPHRINE 0.005MG/ML, LIDOCAINE HYDROCHLORIDE 0.5% · INJECTABLE · INJECTION

Approval history

2026-04-01Labeling · Supplement 46 · standardAP
2020-07-15Labeling · Supplement 35 · standardAP
2020-07-15Labeling · Supplement 33 · standardAP
2010-04-12Labeling · Supplement 20AP
2002-12-16Manufacturing (CMC) · Supplement 10AP
2002-01-02Labeling · Supplement 9AP
1998-05-26Manufacturing (CMC) · Supplement 8AP
1998-05-26Manufacturing (CMC) · Supplement 6AP
1997-09-26Manufacturing (CMC) · Supplement 5AP
1995-10-23Manufacturing (CMC) · Supplement 4AP
1990-11-09Labeling · Supplement 3AP
1990-03-21Labeling · Supplement 2AP
1989-07-06Manufacturing (CMC) · Supplement 1AP
1988-06-21OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →